Cevimeline
Pharmaceutical drug
From Wikipedia, the free encyclopedia
Cevimeline (trade name Evoxac) is a synthetic analog of the natural alkaloid muscarine with a particular agonistic effect on M1 and M3 receptors. It is used in the treatment of dry mouth and Sjögren's disease.
| |
 | |
| Clinical data | |
|---|---|
| Trade names | Evoxac |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a608025 |
| Pregnancy category |
|
| Routes of administration | By mouth (capsules) |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | <20% |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C10H17NOS |
| Molar mass | 199.31 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Medical uses
Cevimeline is used in the treatment of xerostomia (dry mouth)[1][2] and Sjögren's syndrome.[1] It increases the production of saliva.[2]
Side effects
Known side effects include nausea, vomiting, diarrhea, excessive sweating, rash, headache, runny nose, cough, drowsiness, hot flashes, blurred vision, and difficulty sleeping.[3]
Contraindications include asthma and angle closure glaucoma.[citation needed]
Mechanism of action
Cevimeline is a cholinergic agonist.[2] It has a particular effect on M1 and M3 receptors.[2] By activating the M3 receptors of the parasympathetic nervous system, cevimeline stimulates secretion by the salivary glands, thereby alleviating dry mouth.
See also
- Pilocarpine — a similar parasympathomimetic medication for dry mouth (xerostomia)
- Bethanechol — a similar muscarinic parasympathomimetic with longer-lasting effect